Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antigen‐specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapy

23 Mar 2016

Abstract excerpt

Tumor infiltrating lymphocyte (TIL) therapy has shown objective clinical response rates of 50% in stage IV melanoma patients in a number of clinical trials. Nevertheless, the majority of patients progress either directly upon therapy or after an initial period of tumor control. Recent data have shown that most TIL products that are used for therapy contain only low frequencies of T cells reactive against known...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27005018
DOI: 10.1002/eji.201545849

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antigen‐specific TIL therapy for melanoma: A flexible platform for personalized cancer immunotherapyPMID 27005018Read ↗

Neoantigen-specific CD4+ tumor-infiltrating lymphocytes are potent effectors identified within adoptive cell therapy products for metastatic melanoma patientsSemantic proximity Read ↗

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsSemantic proximity Read ↗

Affinity, specificity and T-cell-receptor diversity of melanoma-specific CTL generated in vitro against a single tyrosinase epitope.Semantic proximity Read ↗

Phenotypic and Functional Characteristics of CD8+ T Cells Predict Clinical Outcome Following TIL Therapy in a Randomized Phase III Trial in Advanced Melanoma.Semantic proximity Read ↗

Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1.Semantic proximity Read ↗

Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers.Semantic proximity Read ↗

Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.Semantic proximity Read ↗

TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapySemantic proximity Read ↗

Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients.Semantic proximity Read ↗

Melanoma antigens recognised by CD8+ and CD4+ T cells.Semantic proximity Read ↗

Identification of highly cross-reactive mimotopes for a public T cell response in murine melanomaSemantic proximity Read ↗

Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.